

# Julia Scarisbrick

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6229217/publications.pdf>

Version: 2024-02-01

105  
papers

6,762  
citations

94433

37  
h-index

64796

79  
g-index

108  
all docs

108  
docs citations

108  
times ranked

4496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA–IIA Mycosis Fungoides. <i>Dermatology</i> , 2022, 238, 347-357.	2.1	9
2	Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. <i>Blood</i> , 2022, 140, 419-437.	1.4	58
3	Clinical, histopathological and prognostic features of primary cutaneous acral <sup>+</sup> Tâ€cell lymphoma and other dermal <sup>+</sup> cutaneous lymphoproliferations: results of an <sup>+</sup> EORTC</sup> Cutaneous Lymphoma Group workshop*. <i>British Journal of Dermatology</i> , 2022, 186, 887-897.	1.5	12
4	Costâ€effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 193-202.	1.4	1
5	Chlormethine Gel Versus Chlormethine Ointment for Treatment of Patients with Mycosis Fungoides: A Post-Hoc Analysis of Clinical Trial Data. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 561-570.	6.7	2
6	The PROCLIFI international registry, an important tool to evaluate the prognosis of cutaneous T cell lymphomas. <i>Presse Medicale</i> , 2022, 51, 104123.	1.9	6
7	Treatment of earlyâ€stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIFI) study*. <i>British Journal of Dermatology</i> , 2021, 184, 722-730.	1.5	39
8	Should we be imaging lymph nodes at initial diagnosis of earlyâ€stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIFI) international study*. <i>British Journal of Dermatology</i> , 2021, 184, 524-531.	1.5	18
9	The importance of assessing blood tumour burden in cutaneous Tâ€cell lymphoma*. <i>British Journal of Dermatology</i> , 2021, 185, 19-25.	1.5	12
10	Phenotypical Markers, Molecular Mutations, and Immune Microenvironment as Targets for New Treatments in Patients with Mycosis Fungoides and/or SÃ©zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2021, 141, 484-495.	0.7	31
11	The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous Tâ€cell lymphoma. <i>British Journal of Haematology</i> , 2021, 192, 683-696.	2.5	24
12	Maintenance therapy in patients with mycosis fungoides or SÃ©zary syndrome: A neglected topic. <i>European Journal of Cancer</i> , 2021, 142, 38-47.	2.8	17
13	Realâ€world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/SÃ©zary syndrome. <i>British Journal of Dermatology</i> , 2021, 184, 978-981.	1.5	6
14	European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 â€“ Part 2. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 27-49.	2.4	28
15	Cutaneous T-cell lymphoma: practical recommendations to enhance clinical practice. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2021, 82, 1-6.	0.5	0
16	Response to brentuximab vedotin versus physicianâ€™s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021, 148, 411-421.	2.8	27
17	Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 1601-1604.e2.	0.7	22
18	Cutaneous T cell lymphoma. <i>Nature Reviews Disease Primers</i> , 2021, 7, 61.	30.5	70

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2225-2238.	2.4	16
20	Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and S�azary syndrome with variable CD30 positivity*. <i>British Journal of Dermatology</i> , 2021, 185, 1035-1044.	1.5	15
21	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician��s choice in cutaneous T-cell lymphoma: final data. <i>Blood Advances</i> , 2021, 5, 5098-5106.	5.2	46
22	Prognostic factors in mycosis fungoides and S�azary syndrome: results from the PROCLIFI study. <i>European Journal of Cancer</i> , 2021, 156, S28-S29.	2.8	0
23	Treatment efficacy for S�azary syndrome: an international, multi-centre, comparative study of current systemic therapies. <i>European Journal of Cancer</i> , 2021, 156, S20.	2.8	0
24	Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T cell lymphoma at a tertiary care centre. <i>European Journal of Cancer</i> , 2021, 156, S55.	2.8	1
25	Characteristics associated with significantly worse quality of life in mycosis fungoides/S�azary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index ( ) Tj ETQq1 1 0.784314 rgBT��verlock7�� Tf 504		
26	Brentuximab a novel antibody therapy: real��world use confirms efficacy and tolerability for CD30��positive cutaneous lymphoma. <i>British Journal of Dermatology</i> , 2020, 182, 799-800.	1.5	12
27	Evaluation of haematopoietic stem cell transplantation in patients diagnosed with cutaneous T��cell lymphoma at a tertiary care centre: should we avoid chemotherapy in conditioning regimens?. <i>British Journal of Dermatology</i> , 2020, 182, 807-809.	1.5	12
28	European dermatology forum �� updated guidelines on the use of extracorporeal photopheresis 2020 �� part 1. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2693-2716.	2.4	49
29	Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma. <i>Cancers</i> , 2020, 12, 2311.	3.7	38
30	UK national audit of extracorporeal photopheresis (ECP) in chronic graft versus host disease. <i>Leukemia and Lymphoma</i> , 2020, 61, 3511-3514.	1.3	1
31	A survey of extracorporeal photopheresis treatment in pediatric patients in the United Kingdom. <i>EJHaem</i> , 2020, 1, 293-296.	1.0	1
32	Management of primary cutaneous lymphoma patients during COVID��19 pandemic: EORTC CLTF guidelines. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1633-1636.	2.4	14
33	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. <i>European Journal of Cancer</i> , 2020, 133, 120-130.	2.8	21
34	Blockade of programmed cell death protein 1 (PD-1) in S�azary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. <i>Oncolmmunology</i> , 2020, 9, 1738797.	4.6	32
35	Survival in Mycosis Fungoides and Sezary Syndrome: How Can We Predict Outcome?. <i>Journal of Investigative Dermatology</i> , 2020, 140, 281-283.	0.7	16
36	FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL). <i>Hematological Oncology</i> , 2019, 37, 286-288.	1.7	2

#	ARTICLE	IF	CITATIONS
37	Prognostic factors in mycosis fungoides: the PROCLIFI study. <i>European Journal of Cancer</i> , 2019, 119, S26.	2.8	1
38	Brentuximab vedotin (BV) versus physician's choice (PC) of methotrexate or bexarotene in adult patients with previously treated CD30-positive cutaneous T-cell lymphoma (CTCL; mycosis fungoides) results from the phase 3 ALCANZA study. <i>European Journal of Cancer</i> , 2019, 119, S31.	2.8	1
39	Health-related Quality of Life in Cutaneous Lymphomas: Past, Present and Future. <i>Acta Dermato-Venereologica</i> , 2019, 99, 640-646.	1.3	26
40	Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR. <i>Blood Advances</i> , 2019, 3, 519-530.	5.2	25
41	EFFICACY OF MOGAMULIZUMAB IN PREVIOUSLY TREATED PATIENTS WITH LESS ADVANCED MYCOSIS FUNGOIDES: RESULTS FROM THE MAVORIC STUDY. <i>Hematological Oncology</i> , 2019, 37, 66-67.	1.7	1
42	TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T-CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST-HOC ANALYSIS OF THE MAVORIC STUDY. <i>Hematological Oncology</i> , 2019, 37, 285-286.	1.7	3
43	British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. <i>British Journal of Dermatology</i> , 2019, 180, 496-526.	1.5	111
44	Ethnicity in mycosis fungoides: white patients present at an older age and with more advanced disease. <i>British Journal of Dermatology</i> , 2019, 180, 1264-1265.	1.5	6
45	Secukinumab for treatment of psoriasis: does secukinumab precipitate or promote the presentation of cutaneous T-cell lymphoma?. <i>Clinical and Experimental Dermatology</i> , 2019, 44, 414-417.	1.3	21
46	The PROCLIFI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. <i>British Journal of Dermatology</i> , 2019, 181, 350-357.	1.5	127
47	Safety of Mogamulizumab in Mycosis Fungoides and S�zary Syndrome: Final Results from the Phase 3 Mavoric Study. <i>Blood</i> , 2019, 134, 5300-5300.	1.4	3
48	Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7539-7539.	1.6	4
49	Update on skin directed therapies in mycosis fungoides. <i>Chinese Clinical Oncology</i> , 2019, 8, 7-7.	1.2	38
50	Blood classification and blood response criteria in mycosis fungoides and S�zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. <i>European Journal of Cancer</i> , 2018, 93, 47-56.	2.8	105
51	516 Global collaboration for establishment of a prognostic index in mycosis fungoides & S�zary Syndrome. <i>Journal of Investigative Dermatology</i> , 2018, 138, S88.	0.7	3
52	The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and S�zary Syndrome. <i>American Journal of Surgical Pathology</i> , 2018, 42, 726-734.	3.7	17
53	Computed tomography scanning in mycosis fungoides: optimizing the balance between benefit and harm. <i>British Journal of Dermatology</i> , 2018, 178, 563-564.	1.5	3
54	U.K. national audit of extracorporeal photopheresis in cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2018, 178, 569-570.	1.5	8

#	ARTICLE	IF	CITATIONS
55	Infections in mycosis fungoides and S�zary syndrome are a frequent cause of morbidity and contribute to mortality. What can be done?. British Journal of Dermatology, 2018, 179, 1243-1244.	1.5	10
56	542 Changes in blood involvement in Sezary syndrome positively correlate with skin severity but not in mycosis fungoides. Journal of Investigative Dermatology, 2018, 138, S92.	0.7	3
57	Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome. European Journal of Cancer, 2018, 101, 278-280.	2.8	10
58	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncology, The, 2018, 19, 1192-1204.	10.7	398
59	The role of extracorporeal photopheresis in the management of cutaneous T�cell lymphoma, graft�versus�host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. British Journal of Haematology, 2017, 177, 287-310.	2.5	109
60	Biopsy correlation of surface area vs. single�axis measurements on computed tomography scan of lymph nodes in patients with erythrodermic mycosis fungoides and S�zary syndrome. British Journal of Dermatology, 2017, 177, 877-878.	1.5	7
61	Prognostic factors in mycosis fungoides: international advances in the validation of prognostic indices. British Journal of Dermatology, 2017, 176, 1129-1130.	1.5	6
62	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet, The, 2017, 390, 555-566.	13.7	444
63	The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group. International Journal of Radiation Oncology Biology Physics, 2017, 99, 627-633.	0.8	59
64	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/S�zary syndrome � Update 2017. European Journal of Cancer, 2017, 77, 57-74.	2.8	363
65	Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Annals of Oncology, 2017, 28, 2517-2525.	1.2	98
66	Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management. Future Oncology, 2017, 13, 2405-2411.	2.4	14
67	Image Gallery: Secondary cutaneous involvement of the ear with systemic small lymphocytic lymphoma: a rare manifestation. British Journal of Dermatology, 2017, 177, e26-e26.	1.5	1
68	Primary cutaneous B-cell lymphoma: systemic spread is rare while cutaneous relapses and secondary malignancies are frequent. British Journal of Dermatology, 2017, 177, 287-289.	1.5	11
69	Brentuximab vedotin is an effective therapy for CD30<sup>+</sup> mycosis fungoides and cutaneous anaplastic large-cell lymphoma: what is the cost?. British Journal of Dermatology, 2017, 177, 1474-1475.	1.5	4
70	Unmasking mycosis fungoides/S�zary syndrome from preceding or co-existing benign inflammatory dermatoses requiring systemic therapies: patients frequently present with advanced disease and have an aggressive clinical course. British Journal of Dermatology, 2016, 174, 901-904.	1.5	19
71	New treatment options for mycosis fungoides. Indian Journal of Dermatology, 2016, 61, 119.	0.3	27
72	Stage I mycosis fungoides: frequent association with a favourable prognosis but disease progression and disease-specific mortality may occur. British Journal of Dermatology, 2015, 173, 1295-1297.	1.5	20

#	ARTICLE	IF	CITATIONS
73	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and SÅ©zary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2015, 33, 3766-3773.	1.6	328
74	Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD. <i>Bone Marrow Transplantation</i> , 2014, 49, 704-708.	2.4	26
75	Extracorporeal photopheresis for treatment of adults and children with acute GVHD: UK consensus statement and review of published literature. <i>Bone Marrow Transplantation</i> , 2014, 49, 1251-1258.	2.4	41
76	Guidelines on the use of extracorporeal photopheresis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1-37.	2.4	212
77	Prognostic factors, prognostic indices and staging in mycosis fungoides and SÅ©zary syndrome: where are we now?. <i>British Journal of Dermatology</i> , 2014, 170, 1226-1236.	1.5	121
78	A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. <i>European Journal of Cancer</i> , 2013, 49, 2859-2868.	2.8	121
79	Prevalence and Severity of Pruritus and Quality of Life in Patients With Cutaneous T-Cell Lymphoma. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 114-119.	1.2	74
80	U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2013, 168, 192-200.	1.5	81
81	Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. <i>British Journal of Cancer</i> , 2013, 109, 2566-2573.	6.4	35
82	Pediatric cutaneous lymphomas: rare diseases requiring expert diagnosis and management. <i>Expert Review of Dermatology</i> , 2013, 8, 489-499.	0.3	1
83	Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD. <i>Bone Marrow Transplantation</i> , 2012, 47, 824-830.	2.4	58
84	Diagnosis and management of chronic graftâ€versusâ€host disease. <i>British Journal of Haematology</i> , 2012, 158, 46-61.	2.5	152
85	<scp>D</scp>iagnosis and management of acute graftâ€versusâ€host disease. <i>British Journal of Haematology</i> , 2012, 158, 30-45.	2.5	281
86	Poikilodermatous mycosis fungoides: AÅstudy of its clinicopathological, immunophenotypic, and prognostic features. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 313-319.	1.2	62
87	Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4485-4491.	1.6	604
88	Survival Outcomes and Prognostic Factors in Mycosis Fungoides/SÅ©zary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal. <i>Journal of Clinical Oncology</i> , 2010, 28, 4730-4739.	1.6	675
89	Positive Effect of Extracorporeal Photopheresis In Reducing Immunosuppression in Patients with Chronic Graft Versus Host Disease.. <i>Blood</i> , 2010, 116, 3452-3452.	1.4	0
90	Bexarotene therapy for mycosis fungoides and SÅ©zary syndrome. <i>British Journal of Dermatology</i> , 2009, 160, 1299-1307.	1.5	96

#	ARTICLE	IF	CITATIONS
91	Extracorporeal photopheresis: what is it and when should it be used?. <i>Clinical and Experimental Dermatology</i> , 2009, 34, 757-760.	1.3	30
92	U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. <i>British Journal of Dermatology</i> , 2008, 158, 659-678.	1.5	160
93	Staging and management of cutaneous T-cell lymphoma. <i>Clinical and Experimental Dermatology</i> , 2006, 31, 181-186.	1.3	39
94	A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides. <i>Clinical and Experimental Dermatology</i> , 2004, 29, 231-236.	1.3	41
95	Microsatellite Instability Is Associated with Hypermethylation of the hMLH1 Gene and Reduced Gene Expression in Mycosis Fungoides. <i>Journal of Investigative Dermatology</i> , 2003, 121, 894-901.	0.7	52
96	Frequent Abnormalities of the P15 and P16 Genes in Mycosis Fungoides and Sezary Syndrome. <i>Journal of Investigative Dermatology</i> , 2002, 118, 493-499.	0.7	106
97	Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. <i>British Journal of Dermatology</i> , 2002, 147, 464-475.	1.5	153
98	Cutaneous lymphoma. , 2001, , 233-251.		0
99	Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. <i>Blood</i> , 2001, 97, 624-630.	1.4	142
100	Extracorporeal photopheresis in Sezary syndrome: hematologic parameters as predictors of response. <i>Blood</i> , 2001, 98, 1298-1301.	1.4	73
101	A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2001, 144, 1010-1015.	1.5	50
102	Systemic Hodgkin's lymphoma in a patient with Sezary syndrome. <i>British Journal of Dermatology</i> , 2000, 142, 771-775.	1.5	8
103	Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN. <i>Blood</i> , 2000, 95, 2937-42.	1.4	20
104	Regional lymphomatoid papulosis: a report of four cases. <i>British Journal of Dermatology</i> , 1999, 141, 1125-1128.	1.5	63
105	Cutaneous graft-versus-host-like reaction in systemic T-cell lymphoma. <i>Clinical and Experimental Dermatology</i> , 1999, 24, 382-384.	1.3	2